Amylin Pharmaceuticals, Inc. Release: Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes

PHILADELPHIA--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced clinical study results which showed that a significantly greater proportion of patients treated with BYDUREON™ (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, achieved target glucose levels and weight loss compared to those treated with Levemir®(insulin detemir). The study is being presented at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia.